A share price of Supernus Pharmaceuticals Inc [SUPN] is currently trading at $38.06, up 1.68%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SUPN shares have gain 5.25% over the last week, with a monthly amount glided 2.39%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Supernus Pharmaceuticals Inc [NASDAQ: SUPN] stock has seen the most recent analyst activity on January 06, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $57. Previously, Piper Sandler downgraded its rating to Neutral on September 11, 2024, and dropped its price target to $36. Jefferies upgraded its rating to a Buy and raised its price target to $40 on April 13, 2021. Piper Sandler upgraded its rating to Overweight for this stock on June 16, 2020, and upped its price target to $31.
Supernus Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $25.53 and $39.37. Currently, Wall Street analysts expect the stock to reach $36 within the next 12 months. Supernus Pharmaceuticals Inc [NASDAQ: SUPN] shares were valued at $38.06 at the most recent close of the market. An investor can expect a potential drop of -5.41% based on the average SUPN price forecast.
Analyzing the SUPN fundamentals
Trailing Twelve Months sales for Supernus Pharmaceuticals Inc [NASDAQ:SUPN] were 651.97M which represents 14.17% growth. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at 0.11%, Pretax Profit Margin comes in at 0.11%, and Net Profit Margin reading is 0.09%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.06 and Total Capital is 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 37.11 points at the first support level, and at 36.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 38.66, and for the 2nd resistance point, it is at 39.25.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Supernus Pharmaceuticals Inc [NASDAQ:SUPN] is 2.20. As well, the Quick Ratio is 1.98, while the Cash Ratio is 0.11. Considering the valuation of this stock, the price to sales ratio is 3.22, the price to book ratio is 2.09 and price to earnings (TTM) ratio is 35.63.
Transactions by insiders
Recent insider trading involved Bhatt Padmanabh P., Sr. VP of IP, CSO, that happened on Dec 03 ’24 when 21495.0 shares were sold. Officer, PADMANABH P BHATT completed a deal on Dec 03 ’24 to buy 21495.0 shares. Meanwhile, Director NEWHALL CHARLES W III sold 10700.0 shares on Nov 11 ’24.
